Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11260MR)

This product GTTS-WQ11260MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11260MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4896MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ8055MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ2138MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ4058MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ1451MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ370MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15510MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ10068MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW